R1

AML’s Frontline Future Starts With Finding the Mutation Fast

FSHD Gets a Stronger Biological Signal

ALS Immunotherapy Moves Into the Extension Phase

Eli Lilly’s retatrutide could reset obesity care, but rising demand and grey-market access are testing regulators and health systems

Metabolic health is no longer just a clinic problem. It is a city, climate and equity problem

Can AstraZeneca challenge the obesity market leaders? New GLP-1 data signal growing ambitions beyond oncology

GIST Care Looks Beyond First-Generation KIT Control

Pancreatic Cancer Finally Gets a RAS Moment

A Rare Pain Disorder Gets a Pivotal Trial
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
